<DOC>
	<DOC>NCT03082235</DOC>
	<brief_summary>Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Nonsmoking, male or female, age ≥18 years and ≤45 years old at the time of informed consent Body mass index (BMI) ≥18 and &lt;32 kilograms per meters squared (kg/m2) at Screening Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive betahuman chorionic gonadotropin [βhCG] or human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 International Units per Liter [IU/L] or equivalent units of βhCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period and for 5 times the halflife of the study drug plus 90 days after study drug discontinuation). No sperm donation is allowed during the study period and for 5 times the halflife of the study drug plus 90 days after study drug discontinuation. Any history of gastrointestinal surgery that may affect pharmacokinetic (PK) profiles of E6742 (eg, hepatectomy, nephrectomy, digestive organ resection) at Screening Known history of clinically significant drug allergy at Screening Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening Known to be human immunodeficiency virus (HIV) positive at Screening Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening History of drug or alcohol dependency or abuse within the 2 years prior to Screening, or those who have a positive urine drug and alcohol test at Screening or Baseline Currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 halflives, whichever is longer) before informed consent Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week before dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy participants</keyword>
	<keyword>E6742</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>